Search
lanthanum carbonate (La2[CO3]3, Fosrenol)
Tradename: Fosrenol
Indications:
- reduction of serum phosphorus in patient with end-stage renal disease
Contraindications:
Pregnancy category: C
Dosage:
1) start 760-1500 mg QD in divided doses
2) increase as needed at 2 week intvervals in 750 mg increments
3) most patients require* 1500-3000 mg QD
Tabs: 250 & 500 mg (elemental lanthunum)
* requirement assessed by serum phosphate < 6 mg/dL
Adverse effects:
1) nausea/vomiting 10%
2) dialysis graft occlusion 8%
3) abdominal pain 8%
Mechanism of action:
- La+2-containing phosphate-binder
General
phosphate binder
salt
Database Correlations
PUBCHEM cid=176168
References
- Prescriber's Letter 11(12): 2004
New Drug: Lanthanum Carbonate (Fosrenol)
Detail-Document#: 201209
(subscription needed) http://www.prescribersletter.com
- http://www.fosrenol.com
Components
La+3